Akriderm cream d / pl. approx. 0.05% tube 30g

Release form, composition and packaging

Cream for external use 0.05% white or off-white

100 g

betamethasone dipropionate in terms of 100% substance 0.064 g,

which is equivalent to betamethasone 0.05 g

methyl parahydroxybenzoate - 0.2 g, solid paraffin - 9 g, petroleum jelly - 3 g, propylene glycol - 5 g, liquid paraffin - 18 g, emulsion wax - 7 g, disodium edetate - 0.1 g, sodium sulfite - 0.05 g, purified water - up to 100 r

15 g - aluminum tubes (1) - cardboard packs.

30 g - aluminum tubes (1) - cardboard packs.

50 g - aluminum tubes (1) - cardboard packs.

pharmachologic effect

GCS, has anti-inflammatory, antipruritic and vasoconstrictor effects. ''

Indications for use

allergic skin diseases (including acute, subacute and chronic contact dermatitis, occupational dermatitis, solar dermatitis, neurodermatitis, pruritus, dyshidrotic dermatitis)

acute and chronic forms of non-allergic dermatitis

psoriasis.

Contraindications for use

lupus

viral skin infections

vaccination

perioral dermatitis

rosacea (rosacea)

hypersensitivity to any component of the drug.

Dosage regimen

Akriderm should be applied in a thin layer to the affected areas 1-3 times / day, rubbing lightly.

The duration of treatment should be no more than 3 weeks

The use of Akriderm in children under the age of 12 is carried out under the supervision of a physician.

Overdose

Symptoms: excessive or prolonged use of local GCS can cause inhibition of the function of the pituitary-adrenal system, which can lead to the development of secondary adrenal cortex insufficiency and the appearance of symptoms of hypercortisolism, including Cushing's syndrome.

Treatment: Appropriate symptomatic treatment is indicated.

Acute symptoms of hypercortisolism are usually reversible.

Correction of electrolyte imbalance is indicated if necessary.

In the case of chronic toxic effects, a gradual abolition of GCS is recommended.

Side effect

Possible: burning, irritation and dryness of the skin, folliculitis, hypertrichosis, hypopigmentation, allergic contact dermatitis, skin atrophy, striae and prickly heat.

In case of side effects, you should consult a doctor.

Drug interactions

There were no clinically significant interactions with other drugs.

Application during pregnancy and lactation

Due to the fact that the safety of using local corticosteroids in pregnant women has not been established, the use of drugs of this class during pregnancy is justified only if the benefits to the mother clearly outweigh the possible harm to the fetus.

Drugs in this group should not be used by pregnant women in large doses for a long time.

Since it has not yet been established whether glucocorticosterones, when applied topically and systemically absorbed, can penetrate into breast milk, a decision should be made to stop breastfeeding or to discontinue the drug, taking into account how necessary its use for the mother.

Special instructions In the absence of the effect of treatment within two weeks, it is recommended to consult your doctor in order to possibly clarify the diagnosis.

If irritation or hypersensitivity reaction is noted during the use of the drug, treatment should be discontinued and consult your doctor.

For secondary fungal or bacterial infections, appropriate medications should be used.

In the absence, at the same time, of a quick positive effect, the use of Akriderm should be discontinued until all signs of infection are eliminated

Long-term use of the drug on the skin is not recommended.

Do not use Akriderm in the eye area, because

in this case, the development of cataracts, glaucoma, fungal infection and exacerbation of herpes infection is possible

Use in pediatrics

Children may be more receptive

Name ENG

AKRIDERM GK

Clinical and pharmacological group

GCS for local use + antibiotic aminoglycoside + antifungal agent

ATX code

Betamethasone in combination with other drugs

Dosage

0.05% x 30g

Structure

betamethasone dipropionate 64 mg, which corresponds to the content of betamethasone 50 mg.

Excipients: methyl parahydroxybenzoate - 0.2 g, solid paraffin - 9 g, petroleum jelly - 3 g, propylene glycol - 5 g, liquid paraffin - 18 g, emulsion wax - 7 g, disodium edetate - 0.1 g, sodium sulfite - 0.05 g, purified water - up to 100 g.

Indications

allergic skin diseases (including acute, subacute and chronic contact dermatitis, occupational dermatitis, solar dermatitis, neurodermatitis, pruritus, dyshidrotic dermatitis)

acute and chronic forms of non-allergic dermatitis

psoriasis.

Storage conditions and periods

At a temperature of 15-25 degrees.

Expiration date: 4 years

INN / Active ingredient

betamethasone

Contraindications

lupus

viral skin infections

vaccination

perioral dermatitis

rosacea (rosacea)

hypersensitivity to any component of the drug.

Specifications

Category

Psoriasis

Scope of the drug

Dermatology

Release form

Cream

Manufacturer country

Russia

Package quantity, pcs

one

Scope of application

Dermatology

,

Allergology

Minimum age from

2 years old

Way of introduction

Locally

,

Outwardly

Vacation conditions

Without recipe

Brand name

Akrikhin

The amount of the dosage form in the primary package

30 g

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Topical glucocorticosteroid

Anatomical and therapeutic characteristics

D07AC01 Betamethasone

Dosage form

Cream for external use

Expiration date in days

1460

Dosage (volume) of the substance in the preparation

betamethasone dipropionate 64 mg

Package weight, g

45

Mode of application

:

Akriderm should be applied in a thin layer to the affected areas 1-3 times / day, rubbing lightly.

The duration of treatment should be no more than 3 weeks. The use of Akriderm in children under the age of 12 is carried out under the supervision of a doctor.

Information on technical characteristics, delivery set, country of manufacture